Transgene Biotek MD and chairman
BSE: 526139Healthcare ServicesSmall Cap
Share price at the BSE close on 30 Oct 2026. Previous close ₹2.42.
30 Oct: open ₹2.59, high ₹2.59, low ₹2.26
- Under BSE's graded surveillance, stage 0, on the list for 29 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹18 Cr4,238th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.11
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −17.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −2.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 2.05
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 43,282
Transgene Biotek's chairperson and managing director is K KOTESWARA RAO, as filed for the quarter to Sep 2026.
Transgene Biotek board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.
- Chairperson and managing directorK KOTESWARA RAORelated to the promoter
- Company Secretary and Compliance OfficerANKITA JAIN
4 directors3 independent1 executive
- K KOTESWARA RAO · Chairperson and managing directorExecutive · joined Mar 1990 · reappointed Dec 2025 · 439 months as independent · 1 listed board · 1 committee seat, 1 as chair
- SUJANA KADIAMIndependent · joined Apr 2015 · 137 months as independent · 1 listed board · 1 as independent · 1 committee seat, 1 as chair
- SANTHOSH KUMARIndependent · joined Nov 2019 · 83 months as independent · 1 listed board · 1 as independent · 1 committee seat, 1 as chair
- SWETHA MARRIIndependent · joined Jun 2020 · 84 months as independent · 1 listed board · 1 as independent · 1 committee seat, 1 as chair
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 7 Aug 20264 of 4 present3 independent · 69 days in between
- 29 May 20264 of 4 present3 independent
Audit Committee
Chair SUJANA KADIAM
K KOTESWARA RAO, SANTHOSH KUMAR
- 7 Aug 20263 of 3 present2 independent · 69 days in between
- 29 May 20263 of 3 present2 independent
Nomination and remuneration committee
Chair SUJANA KADIAM
K KOTESWARA RAO, SANTHOSH KUMAR
- 7 Aug 20263 of 3 present2 independent
Stakeholders Relationship Committee
Chair SUJANA KADIAM
K KOTESWARA RAO, SANTHOSH KUMAR
No meeting listed in the filing.
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Jun 2026.
- VASAVI & COPeer-review certificate valid to Nov 2026
1 earlier auditor
- VASAVI AND CONamed in the filing for the quarter to Jun 2025
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.